Betrixaban approved in the USA for Medical Prophylaxis for high risk patients

In a recent article in the New England Journal of Medicine a trial involving Betrixaban, a direct factor Xa inhibitor, in extended prophylaxis for acutely unwell medical patients comparing this with Enoxaparin injections. The full article can be accessed here


This medication however is currently only licensed in the United States where it has received FDA approval and can not currently be used in Europe